Researchers tested a new GLP-1 pill, orforglipron, in adults with type 2 diabetes.
Eli Lilly developed the drug as an oral alternative to injectable treatments.
The medication lowers blood sugar, slows digestion, and reduces appetite.
Patients can take it without fasting.
Regulators in the US and Europe have not yet approved it.
In a phase 3 trial, more than 1,500 participants received treatment for one year.
Researchers compared two doses of orforglipron with oral semaglutide.
Patients taking orforglipron lost six to eight percent of their body weight.
Those taking semaglutide lost four to five percent.
Orforglipron also improved blood sugar control more strongly.
More patients stopped orforglipron because of gastrointestinal side effects.
Experts say convenient tablets could expand access to obesity and diabetes treatment.
